購(gòu)物車
幫助
021-54845833/15800441009
|
Background: |
The 21 kDa guanine-nucleotide binding proteins (K-Ras, H-Ras, and N-Ras) cycle between active (GTP-bound) and inactive (GDP-bound) forms. Receptor tyrosine kinases and G protein-coupled receptors activate Ras, which then stimulates the Raf-MEK-MAPK pathway. GTPase-activating proteins (GAP) normally facilitate the inactivation of Ras. However, research studies have shown that in 30% of human tumors, point mutations in Ras prevent the GAP-mediated inhibition of this pathway. The most common oncogenic Ras mutation found in tumors is Gly12 to Asp12 (G12D), which prevents Ras inactivation, possibly by increasing the overall rigidity of the protein. |
|
Applications: |
WB |
|
Name of antibody: |
KRAS |
|
Immunogen: |
Fusion protein of human KRAS |
|
Full name: |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
Synonyms： |
KRAS; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KI-RAS; KRAS1; KRAS2; NS3; RASK2 |
|
SwissProt: |
P01116 |
|
WB Predicted band size: |
21 kDa |
|
WB Positive control: |
Brain tissue |
|
WB Recommended dilution: |
500-2000 |
